In the original publication "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus," by Black et al. (2018), the authors regret the errors found in Table 1; Boxes 1, 3, and 4; and Figure 1. The correct Table 1, Boxes 1, 3, and 4, and Figure 1 are given below. (Table Presented). (Figure Presented). In addition, the authors would like to make the following text corrections and clarifications: Page 405: • The MDS EBM was published in 2011. Page 406: • The doses in the early phase 2b/3 study were placebo, 8.5, and 34 mg/d. • The P-value for the hallucination and delusions subscales was 0.0012. • Sleep quality, caregiver burden, etc. were exploratory outcomes. Page 407: • The QT prolongation for pimavanserin is 5-8 msec. The original publication has been corrected to reflect these changes.
All Science Journal Classification (ASJC) codes
- Clinical Neurology
- Psychiatry and Mental health